tradingkey.logo

USANA Health Sciences reports Q4 net sales rise

ReutersFeb 17, 2026 9:24 PM


Overview

  • Nutritional supplements maker's fiscal Q4 net sales rose 6% yr/yr

  • Adjusted diluted EPS for fiscal Q4 fell 6% yr/yr

  • Company anticipates flat to 8% growth in fiscal 2026 net sales


Outlook

  • USANA projects fiscal 2026 consolidated net sales between $925 mln and $1 bln

  • Company expects fiscal 2026 net earnings between $20.3 mln and $26.6 mln

  • USANA anticipates Hiya net sales of $140 mln to $155 mln in fiscal 2026


Result Drivers

  • CUSTOMER STABILIZATION - Co noted signs of stabilization in active customer counts in core nutritional business, with modest sequential sales growth in key markets like China, US, and Canada

  • OMNICHANNEL GROWTH - Hiya and Rise brands experienced solid year-over-year growth, contributing to overall sales increase

  • CORE BUSINESS DECLINE - Core nutritional business sales fell 8% in FY 2025, reflecting challenges in customer acquisition


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 EPS

-$0.10


Analyst Coverage

  • Wall Street's median 12-month price target for USANA Health Sciences Inc is $39.00, about 86.6% above its February 13 closing price of $20.90

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nBw7jfm7Ka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI